Sera Prognostics, Inc.

NasdaqGM SERA

Sera Prognostics, Inc. Current Liabilities for the quarter ending September 30, 2024

Sera Prognostics, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Sera Prognostics, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 13.54 M, a 56.28% change year over year.
Sera Prognostics, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 8.67 M, a 144.62% change year over year.
Sera Prognostics, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 3.54 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGM: SERA

Sera Prognostics, Inc.

CEO	Ms. Evguenia Lindgardt M.B.A.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way
Employees	55
Sector	Healthcare
Industries Biotechnology 3D Printing Baby & Childcare Clinical Trials Cosmetics Personal Care Pharmaceuticals Vaccines

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years